Ograniczanie wyników

Czasopisma help

  1. 19 Cellular and Molecular Biology Letters

  2. 8 Archivum Immunologiae et Therapiae Experimentalis

  3. 7 Acta Biochimica Polonica

  4. 7 Journal of Physiology and Pharmacology

  5. 2 Folia Histochemica et Cytobiologica

Więcej...
Autorzy help

  1. 2 Ginalski K.

  2. 2 Lesyng B.

  3. 1 Ahluwalia A.

  4. 1 Akhthar M. S.

  5. 1 Alama A.

Więcej...
Lata help

  1. 2 2016

  2. 3 2015

  3. 1 2014

  4. 2 2013

  5. 1 2011

Więcej...
Preferencje help
Polish version English version Język
Widoczny [Schowaj] Abstrakt
Liczba wyników

Znaleziono wyników: 50

Liczba wyników na stronie
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 3 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników

Wyniki wyszukiwania

Wyszukiwano:
w słowach kluczowych:  tyrosine kinase
help Sortuj według:

help Ogranicz wyniki do:
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 3 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
1

Crosstalk between G protein-coupled receptors and tyrosine kinase signalling; Src take centre stage

100%
Ptasznik A., Gewirtz A. M.
Archivum Immunologiae et Therapiae Experimentalis
|
2000
|
tom 48
|
nr 1
2

Specific, irreversible inhibitors of the epidermal growth factor receptor [EGFR] family of tyrosine kinases

88%
Fry D. W.
Cellular and Molecular Biology Letters
|
1998
|
tom 03
|
nr 3
3

Phytoestrogen action in Leydig cells of Bilgoraj ganders (Anser anser)

75%
Opalka M., Kaminska B., Puchajda-Skowronska H., Dusza L.
Reproductive Biology
|
2006
|
tom 06
|
nr Suppl.2
4
Artykuł dostępny w postaci pełnego tekstu - kliknij by otworzyć plik
Content available

Tyrosine kinase, Aurora kinase and leucine aminopeptidase as attractive drug targets in anticancer therapy - characterisation of their inhibitors

75%
Ziemska J., Solecka J.
Roczniki Państwowego Zakładu Higieny
|
2016
|
tom 67
|
nr 4
Cancers are the leading cause of deaths all over the world. Available anticancer agents used in clinics exhibit low therapeutic index and usually high toxicity. Wide spreading drug resistance of cancer cells induce a demanding need to search for new drug targets. Currently, many on-going studies on novel compounds with potent anticancer activity, high selectivity as well as new modes of action are conducted. In this work, we describe in details three enzyme groups, which are at present of extensive interest to medical researchers and pharmaceutical companies. These include receptor tyrosine kinases (e.g. EGFR enzymes) and non-receptor tyrosine kinases (Src enzymes), type A, B and C Aurora kinases and aminopeptidases, especially leucine aminopeptidase. We discuss classification of these enzymes, biochemistry as well as their role in the cell cycle under normal conditions and during cancerogenesis. Further on, the work describes enzyme inhibitors that are under in vitro, preclinical, clinical studies as well as drugs available on the market. Both, chemical structures of discovered inhibitors and the role of chemical moieties in novel drug design are discussed. Described enzymes play essential role in cell cycle, especially in mitosis (Aurora kinases), cell differentiation, growth and apoptosis (tyrosine kinases) as well as G1/S transition (leucine aminopeptidase). In cancer cells, they are overexpressed and only their inhibition may stop tumor progression. This review presents the clinical outcomes of selected inhibitors and argues the safety of drug usage in human volunteers. Clinical studies of EGFR and Src kinase inhibitors in different tumors clearly show the need for molecular selection of patients (to those with mutations in genes coding EGFR and Src) to achieve positive clinical response. Current data indicates the great necessity for new anticancer treatment and actions to limit off-target activity.
5
Artykuł dostępny w postaci pełnego tekstu - kliknij by otworzyć plik
Content available

Identification of potential off-targets of chemotherapeutic agent Sorafenib: a molecular docking approach

75%
Sahrawat T. R., Chawla P.
International Letters of Natural Sciences
|
2016
|
tom 51
B-Raf is a multi- drug target serine/threonine protein kinase, involved in the transduction of mitogenic signals from the cell membrane to the nucleus. Mutated B-Raf causes overactive downstream signaling via MEK and ERK, leading to excessive cell proliferation and survival, independent of growth factors causing cancers such as Pancreatic carcinoma. A novel bi-aryl urea- Sorafenib, is a potent inhibitor of Raf-1 that has been approved for the treatment of a number of cancers including pancreatic cancer. The present investigation was designed to identify the potential off-targets of Sorafenib which could be responsible for its reported undesirable side effects. Molecular docking was used to test the efficacy of structural analogs of Sorafenib against B-Raf using FlexX and it was found that the analog with CID:10151557 had a high potency with minimum number of clashes, low lipophilic score and high match score, similar to Sorafenib. To identify the potential off-target/s of Sorafenib, macromolecular surface similarity detection software MEDIT SA MED-SuMo was used and the results obtained were validated through literature. The possible off-targets obtained belonged to the family of protein tyrosine kinases i.e. VEGFR-2, VEGFR-3, platelet-derived growth factor receptor beta, Flt-3, and c-KIT, each of which were docked with Sorafenib. Based on high docking scores and similarity with B-Raf for its binding site interacting residues, it was concluded that Vascular endothelial growth factor tyrosine kinase receptor (VEGFR) is a potential off-target of anti-cancer chemotherapeutic agent Sorafenib.
6

Evolving the desired compound profile within an LCK project

75%
Baldwin I. R.
Cellular and Molecular Biology Letters
|
2003
|
tom 08
|
nr 2A
7

Effects of angiotensin derivatives [Lang] - filled liposomes on isolated rat aorta

75%
Costuleanu M., Costuleanu N., Foia L., Slatineanu S. M., Costuleanu A., Petrescu G.
Cellular and Molecular Biology Letters
|
1999
|
tom 04
|
nr 2
8
Content available remote

The role of tyrosine kinase in prostaglandin E2 and vanadate-evoked contractions in rabbit duodenum in vitro

75%
Grasa L., Arruebo M. P., Plaza M. A., Murillo M. D.
Journal of Physiology and Pharmacology
|
2006
|
tom 57
|
nr 2
Prostaglandin E2 (PGE2) can interact with at least four cell surface receptors (EP1-EP4) in smooth muscle, which evokes a variety of intracellular responses depending on the G protein to which the cell surface receptors are coupled. The activation of G protein-coupled receptors and receptor tyrosine kinases can lead to the phosphorylation of tyrosine residues of various cellular proteins. The aim of this study was to examine the role of tyrosine phosphorylation in PGE2, vanadate and carbachol-evoked contractions. PGE2, vanadate, and carbachol induced contractile motor responses in the longitudinal smooth muscle of rabbit duodenum. PGE2-evoked contractions decreased in the presence of genistein or tyrphostin B44. PGE2-evoked contractions increased in the presence of vanadate. Vanadate-evoked contractions decreased in the presence of genistein. In contrast, tyrphostin 47 increased the vanadate-evoked contractions. Vanadate-evoked contractions were reduced in the presence of Ca2+-free solutions, verapamil, or indomethacin. U-73122 decreased PGE2-evoked contractions. Carbachol-evoked contractions decreased in the presence of genistein, tyrphostin B44 or tyrphostin 47. Our results suggest that PGE2, vanadate or carbachol-evoked contractions are mediated by protein tyrosine phosphorylation. Protein tyrosine phosphorylation might cause an increase in calcium influx through voltage-dependent channels and the release of prostaglandins in the longitudinal smooth muscle of the rabbit duodenum.
9

The transition from a pharmacophore-guided approach to a receptor-guided approach in the design of potent protein kinase C ligands

75%
Marquez V. E., Nacro K., Benzaria S., Lee J., Milne G. W., Bienfait B., Wang S., Lewin N., Blumberg P. M.
Cellular and Molecular Biology Letters
|
1998
|
tom 03
|
nr 3
10

EGF receptor tyrosine kinase inhibitors as anti-cancer agents - pre-clinical and early clinical profile of ZD 1839

75%
Woodburn J. R., Morris C. Q., Kelly H., Laight A.
Cellular and Molecular Biology Letters
|
1998
|
tom 03
|
nr 3
11

WP744, a novel highly apoptotic and antiproliferative agent against STI-571-resistant leukemic cells

75%
Priebe W., Evrony G., Fokt I., Lee S., Talpaz M., Donato N. J.
Cellular and Molecular Biology Letters
|
2003
|
tom 08
|
nr 2A
12
Content available remote

Effects of tyrosine kinase inhibitors on voltage-dependent BA2+ currents in the guinea-pig gastric antrum

75%
Zhu H. L., Ito Y., Teramoto N.
Journal of Physiology and Pharmacology
|
2006
|
tom 57
|
nr 3
We have investigated whether tyrosine kinases modify the activity of voltage-dependent Ba2+ currents (IBa) recorded from guinea-pig gastric myocytes by use of patch-clamp techniques. All experiments were carried on single smooth muscle cells, dispersed from the circular layer of the guinea-pig gastric antrum. Genistein (10 µM), a specific tyrosine kinase inhibitor, reduced the peak amplitude of IBa in a voltage- and concentration-dependent manner. Daidzein (30 µM), an inactive analog of genistein, also inhibited IBa in a concentration-dependent manner. Similarly, other types of tyrosine kinase inhibitors (lavendustin A and tyrphostin 23) suppressed the peak amplitude of IBa in a concentration-dependent manner. These results indicate that tyrosine kinases may be essential to regulate Ca2+ mobilization through voltage-dependent Ca2+ channels in gastric myocytes.
13

Structural basis of oncogenesis caused by point mutations in the kinase domain of the MET proto-oncogene

75%
Miller M., Zbar B., Ginalski K., Lesyng B.
Cellular and Molecular Biology Letters
|
1998
|
tom 03
|
nr 3
14

The role of tyrosine kinase in the adhesion and fusion of myoblasts

75%
Wrobel E., Moraczewski J.
Cellular and Molecular Biology Letters
|
2002
|
tom 07
|
nr Suppl.
15

DNA repair in drug resistance induced by fusion tyrosine kinases

75%
Blasiak J.
Cellular and Molecular Biology Letters
|
2002
|
tom 07
|
nr Suppl.
16

Molecular dissection of fertilisation signalling with the aid of tyrosine-kinase-specific inhibitors

75%
Sato K. I., Iwasaki T., Fukami Y.
Cellular and Molecular Biology Letters
|
2003
|
tom 08
|
nr 2A
17

Effect of protein tyrosine kinases on mitochondrial calcium homeostasis in rat hepatocytes treated with thapsigargin

75%
Walajtys-Rode E., Moehren G., Hoek J. B.
Cellular and Molecular Biology Letters
|
1998
|
tom 03
|
nr 3
18

Regulatory mechanisms for the expression and activity of platelet-derived growth factor receptor

75%
Funa K., Uramoto H.
Acta Biochimica Polonica
|
2003
|
tom 50
|
nr 3
PDGF is one of the most potent serum mitogens, and the signalling mechanism by way of its receptor tyrosine-kinase has been extensively studied since its first purifica­tion in 1979. The identification of homology between the simian sarcoma virus onco­gene, v-sis, and the B-chain of PDGF, as well as the frequent over-expression of both the ligands and receptors in various tumours and stroma led to the proposal of the PDGF-mediated autocrine and paracrine hypothesis. Consistent with the important roles of PDGF in the growth and survival of cells, the expression and activity of PDGF receptors are tightly controlled by both positive and negative feedback mechanisms at different levels. The deregulation of the control system can result in serious pathological conditions such as chronic inflammation and tumours. Understanding the molecular mechanisms for the regulatory system and the signalling pathway of PDGF is essential in order to find effective therapies in the diseases where PDGF is involved.
19

Novel small molecule inhibitors of c-terminal Src kinase [Csk]

75%
Kilimnik A., Kostjukova M. N., Pyatkin I. H., Pronin A. M., Strelnikowa S. R., Fedotov Y. A., Kolesnikov A. V.
Cellular and Molecular Biology Letters
|
2003
|
tom 08
|
nr 2A
20

Structure, regulation and function of PKB-Akt - a major therapeutic target

75%
Hemmings B. A.
Cellular and Molecular Biology Letters
|
2003
|
tom 08
|
nr 2A
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 3 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.